OneSource Specialty Pharma's Q3 FY 2025-26 Quarterly Results
- 24 Jan 2026
Result Summary
- OneSource Specialty Pharma Ltd reported a 22.1% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 25.9%.
- Its expenses for the quarter were up by 2.1% QoQ and 4.7% YoY.
- The net profit decreased 946.4% QoQ and increased 28.8% YoY.
- The earnings per share (EPS) of OneSource Specialty Pharma Ltd declined at 7.74 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 294.96 | 378.80 | 397.96 | -22.1% | -25.9% |
Total Expenses | 380.89 | 373.06 | 363.93 | 2.1% | 4.7% |
Profit Before Tax | -93.01 | 5.74 | -66.50 | -1720.4% | 39.9% |
Tax | -4.31 | -4.74 | 2.35 | -9.1% | -283.4% |
Profit After Tax | -88.70 | 10.48 | -68.85 | -946.4% | 28.8% |
Earnings Per Share | -7.74 | 0.91 | -6.31 | -950.5% | 22.7% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
OneSource Specialty Pharma Ltd is a company operating in the pharmaceutical industry, specializing in the production and distribution of specialty pharmaceutical products. The company's core business activities revolve around the development, manufacturing, and marketing of pharmaceutical products that cater to niche therapeutic areas. OneSource Specialty Pharma Ltd focuses on innovative solutions that address specific medical needs, thereby contributing to the healthcare sector. The company operates in a competitive industry characterized by rapid developments in medical technology and regulatory changes. Information regarding recent major developments specific to OneSource Specialty Pharma Ltd is not available in the provided dataset.
Revenue
In the third quarter of fiscal year 2026 (Q3FY26), OneSource Specialty Pharma Ltd reported a total income of ₹294.96 crores. This represents a quarter-over-quarter (QoQ) decline of 22.1% when compared to the preceding quarter, Q2FY26, where the total income was ₹378.80 crores. Additionally, the year-over-year (YoY) comparison with Q3FY25 indicates a decrease of 25.9%, as the total income in that period was ₹397.96 crores. The decline in total income both on a QoQ and YoY basis is a significant observation from the financial data provided.
Profitability
During the third quarter of fiscal year 2026, OneSource Specialty Pharma Ltd's profitability metrics showed notable fluctuations. The company recorded a loss before tax amounting to ₹93.01 crores, contrasting sharply with a positive figure of ₹5.74 crores in Q2FY26. This represents a substantial QoQ decline of 1720.4%. When compared to Q3FY25, where the loss before tax was ₹66.50 crores, there is a YoY increase in loss by 39.9%. The profit after tax for Q3FY26 was a loss of ₹88.70 crores, a stark decrease from the profit of ₹10.48 crores in Q2FY26, indicating a QoQ change of -946.4%. Compared to a loss of ₹68.85 crores in Q3FY25, the YoY change is 28.8%. Earnings per share (EPS) followed a similar trend, recording a negative value of ₹-7.74 in Q3FY26, compared to ₹0.91 in Q2FY26, marking a QoQ decrease of 950.5%. The YoY change in EPS from Q3FY25's ₹-6.31 reflects an increase in loss by 22.7%.
Operating Metrics
The financial data indicates a rise in total expenses for OneSource Specialty Pharma Ltd in Q3FY26, amounting to ₹380.89 crores. This marks a 2.1% increase from ₹373.06 crores in Q2FY26. When compared to the same quarter in the previous year, Q3FY25, where expenses were ₹363.93 crores, there is a YoY increase of 4.7%. The tax expense recorded a negative value of ₹-4.31 crores in Q3FY26, slightly improving from ₹-4.74 crores in Q2FY26, resulting in a QoQ change of -9.1%. Compared to a positive tax expense of ₹2.35 crores in Q3FY25, the YoY change is -283.4%. These fluctuations in operating metrics provide insight into the financial dynamics of OneSource Specialty Pharma Ltd during the reported period.